ARKG Holdings of IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a biotechnology company that specializes in developing tumor-infiltrating lymphocyte (TIL) therapy, a type of cancer immunotherapy that harnesses the patient's own immune cells to treat cancer. The company generates revenue primarily through collaborations, partnerships, and potential future product sales of its TIL therapy once it obtains regulatory approval and commercialization.
Trades of IOVA in ARKG
The ten most recent trades of Iovance Biotherapeutics in the ARKG ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Aug 14, 2023 | Sell | $733 | 100.00% | 0.00% |
| Aug 10, 2023 | Sell | $2,865 | 79.72% | 0.00% |
| Aug 02, 2023 | Sell | $203,440 | 82.57% | 0.01% |
| Jul 31, 2023 | Sell | $535,957 | 68.67% | 0.02% |
| Jul 28, 2023 | Sell | $2,270,883 | 74.68% | 0.10% |
| Jul 26, 2023 | Sell | $924,366 | 23.46% | 0.04% |
| Jul 25, 2023 | Sell | $1,703,111 | 29.94% | 0.07% |
| Dec 16, 2022 | Sell | $441,384 | 7.69% | 0.02% |
| Dec 15, 2022 | Sell | $32,720 | 0.55% | 0.00% |
| Dec 14, 2022 | Sell | $34,057 | 0.55% | 0.00% |